Bill Douglass is founder and Managing Principal of Gotham Private Capital. He also runs Gotham Communications, a strategic communications agency that he founded in 2009. Clients have included Index Ventures, Ambry Genetics (sold to Konica Minolta for $1 Billion), Advanced Cell Technology (re-branded as Ocata Therapeutics and sold to Astellas Pharma for $379 Million, as covered in The New York Times), and XO1 Ltd. (sold to Janssen Pharma/Johnson & Johnson), as well as family offices, hedge funds and other private equity and venture capital firms.

He currently serves on the Brain Targeting Program (BTP) Advisory Board at the Wyss Institute at Harvard University. From 2022 to 2023, Bill served on the management team at Hevolution Foundation, a global life sciences investor and grant-making organization, where he reported directly to the CEO and sat on the Executive Committee.

A Registered Representative of Stonehaven, LLC, Member FINRA/SIPC, Bill holds the Uniform Securities Agent license (Series 63) and the Private Securities Offerings Representative license (Series 82). He attended Boston University’s College of Communication and earned a BA from the University of Houston. He has spoken at a variety of conferences, including Reuters’ HedgeWorld, IMN Alpha Hedge West, Activist Investing in Canada, and the Horasis Global Meeting. His writings have been published in The Economist magazine and elsewhere, and he has been cited by the BBC as an expert on technology trends.

Having traveled to more than 70 countries and worked across six continents, and with deep experience in East Asia and the Middle East, Bill has built an international network of contacts. He lives in Fairfield County, Connecticut, outside New York City, with his wife, who is a practicing physician, and their two children.